How to access Ocrevus from Pakistan, the named-patient import pathway, 2026
*Clinically reviewed by Reserve Meds AI Clinical and Regulatory Review (see /trust). Last reviewed 2026-05-13.
A Pakistani patient with relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease) and primary progressive multiple sclerosis may receive a prescription for Ocrevus (ocrelizumab) from their treating neurologist with MS expertise. Ocrevus is FDA-approved in the United States and manufactured by Genentech (Roche). It is a humanised CD20-directed monoclonal antibody administered by intravenous infusion. Local availability of Ocrevus in Pakistan can be inconsistent: the drug may not be on every specialty pharmacy's standing formulary, the specific indication may not match what is locally registered, or the strength required may be back-ordered. When that happens, a named-patient import pathway through DRAP remains a legitimate route for the patient whose physician has already prescribed the drug.
This guide explains the pathway, the documentation your physician needs, typical costs and indicative timing, and where Reserve Meds fits in.
The clinical situation
Ocrevus is a humanised CD20-directed monoclonal antibody. Mechanism: a humanised IgG1 monoclonal antibody that binds CD20 on B-cells and mediates depletion through antibody-dependent and complement-dependent mechanisms. Dosing: 600 mg by intravenous infusion every 6 months (after a split first dose of 300 mg twice, 2 weeks apart), per FDA labeling. Baseline workup per FDA labeling includes hepatitis B serologies (HBsAg and anti-HBc), quantitative immunoglobulins, complete blood count, and breast cancer screening per age guidelines. Other important warnings include infusion reactions, infections including hepatitis B reactivation and progressive multifocal leukoencephalopathy, malignancy signal including breast cancer in some studies, and immunoglobulin reduction over time. Your neurologist will discuss the risk-benefit profile and schedule monitoring before initiating therapy.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Is Ocrevus legally importable into Pakistan?
Yes, through the Drug Regulatory Authority of Pakistan (DRAP) named-patient and personal-use import framework, coordinated with the treating facility's pharmacy. Pakistan has an established pathway for specialty medicines approved by reference authorities (US FDA, EMA, MHRA) but not stocked or registered for the specific indication locally.
The DRAP named-patient route allows a Pakistani-licensed physician to request import of a medicine when: (a) the medicine is approved by a recognised reference authority, (b) no clinically equivalent locally registered alternative is suitable for the patient's indication and history, (c) the treating physician takes clinical responsibility for use, and (d) chain of custody is documented from the US source to the administering facility. Applications are typically filed through the dispensing institution's import pharmacy on the physician's behalf, with approval issued on a per-patient, per-cycle quantity basis.
How the pathway works, step by step
- Consultation with your treating neurologist. The prescribing decision is clinical. Your neurologist documents the indication, prior therapies where relevant, and rationale for Ocrevus.
- Baseline screening. Hepatitis B serologies (HBsAg and anti-HBc), quantitative immunoglobulins, complete blood count, and breast cancer screening per age guidelines are confirmed and documented.
- DRAP named-patient application. Your neurologist or the facility's import pharmacy files the application with clinical rationale, patient reference, product strength, quantity requested, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from Genentech (Roche)'s authorised distribution under DSCSA chain-of-custody.
- Cold-chain shipment. Ocrevus requires refrigerated transport at 2 to 8 degrees Celsius. Shipments include temperature-monitored packaging with continuous loggers and tamper-evident seals.
- Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription, and your neurologist initiates therapy.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming diagnosis, prior therapies where relevant, and Ocrevus as the indicated next step
- Verification of their Pakistani medical licence
- A patient identifier, anonymised reference where privacy is preferred
- Documented pre-treatment screening consistent with FDA labeling (see above)
- The planned dosing regimen (600 mg by intravenous infusion every 6 months (after a split first dose of 300 mg twice, 2 weeks apart), per FDA labeling)
- A monitoring plan covering HBV screen, infusion premedication protocol, and breast cancer screening note
Reserve Meds provides a physician documentation kit tailored for CD20-directed MS biologic therapies, including the templates DRAP reviewers commonly request.
Typical costs and indicative timing
Reserve Meds gives you a drug-only reference range plus a transparent delivered quote at intake. As an illustrative composite case, the US cash-pay reference range for a single 600 mg infusion every 6 months of Ocrevus sits in an indicative 2026 band of approximately USD 31,000 to 37,000. International logistics, DRAP documentation handling, cold-chain shipping, and concierge coordination add incremental cost. The delivered quote we issue at intake shows each line separately.
Indicative timing for first dose after cohort intake opens is approximately 3 to 6 weeks from the moment a complete application is submitted, assuming the documentation package is clean on first pass. Refills ship on a rolling cadence aligned to the dosing schedule.
Where Reserve Meds fits in
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Ocrevus specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
- Documentation. Regulatory package tailored for your physician and for DRAP review, including CD20-directed MS biologic class templates.
- Cold-chain logistics. Temperature-monitored, internationally tracked shipment to your named dispensing facility with continuous temperature loggers.
- Concierge case lead. A named point of contact for your family and your physician across the full case arc.
We are a coordinator. We are not the prescriber, not a pharmacy, and not a dispensing facility. All clinical decisions remain with your treating neurologist, and dispensing sits with the licensed Pakistani pharmacy of record. Reserve Meds operates on cash-pay only and does not bill insurance.
What to monitor on Ocrevus
Ocrevus sits in the anti-CD20 class with Briumvi (ublituximab) and Kesimpta (ofatumumab). Four safety signals stand out for the patient and the treating neurology team: hepatitis B reactivation, progressive multifocal leukoencephalopathy (PML) and JC virus, persistent hypogammaglobulinaemia, and infusion reactions. Each is described below with the monitoring cadence and the prescribing-information citation.
Hepatitis B reactivation. Pre-treatment screening for hepatitis B is mandatory before the first Ocrevus dose: HBsAg and anti-HBc (total) at minimum, with anti-HBs added where available (Ocrevus Prescribing Information, section 5.2). Patients with chronic hepatitis B require hepatology co-management and antiviral prophylaxis before B-cell depletion. Patients with resolved hepatitis B (HBsAg negative, anti-HBc positive) need a frank discussion of reactivation risk and a monitoring plan; many centres add periodic HBV DNA testing during therapy. Reference: Ocrevus (ocrelizumab) Prescribing Information, Genentech (Roche), section 5.2.
Progressive multifocal leukoencephalopathy (PML) and JC virus. Anti-CD20 therapies including ocrelizumab carry a class risk for PML, a rare and serious brain infection caused by reactivation of the JC virus in immunosuppressed patients. Symptoms include progressive limb weakness, behavioural and cognitive changes, and disturbance of vision or speech. PML cases on ocrelizumab have been reported in the post-marketing setting, including patients with no prior natalizumab exposure (Ocrevus Prescribing Information, section 5.4). Baseline JC virus antibody serology is not mandated by the FDA label, but most MS neurology programmes order it for risk stratification, particularly when sequencing onto Ocrevus from natalizumab (Tysabri). Any new neurological symptom during treatment, including symptoms that do not fit the patient's prior MS relapse pattern, warrants urgent neurology re-evaluation with MRI. Reference: Ocrevus Prescribing Information, section 5.4, US FDA approval March 2017.
Hypogammaglobulinaemia and immunoglobulin monitoring. Anti-CD20 monoclonal antibodies deplete B-lymphocytes and, with repeated dosing, reduce circulating immunoglobulin levels over time. The Ocrevus label requires baseline measurement of serum immunoglobulins (IgG, IgA, IgM) before treatment initiation, with monitoring during treatment and after discontinuation until B-cell repletion (Ocrevus Prescribing Information, section 5.7). MS-experienced centres typically check quantitative immunoglobulins at baseline and every six months at the maintenance-infusion visit. Persistent hypogammaglobulinaemia, in particular IgG below 4 g/L, increases the risk of serious bacterial infection; immunoglobulin replacement (IVIG) may be considered in consultation with immunology if levels remain low and infections recur. References: Ocrevus Prescribing Information, section 5.7; Hauser SL et al., Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis (OPERA I and II), N Engl J Med 2017;376(3):221-234.
Infusion reactions and premedication. Infusion reactions are among the most frequent adverse events in the OPERA I and II and ORATORIO trials, occurring in approximately 34 percent of Ocrevus-treated patients and most often with the first (Day 1, 300 mg) infusion. Premedication is mandatory before each infusion: methylprednisolone 100 mg IV (or equivalent corticosteroid) approximately 30 minutes pre-infusion, plus an oral or IV antihistamine such as diphenhydramine 25 to 50 mg, plus an antipyretic such as paracetamol 650 mg orally (Ocrevus Prescribing Information, section 2 dosing and administration, and section 5.1). The first dose is split into two 300 mg infusions two weeks apart, each delivered over approximately 2.5 hours with continuous observation; maintenance 600 mg infusions run over approximately 3.5 hours, or 2 hours with the shorter-infusion protocol in eligible patients. Reactions may present as throat tightness, flushing, headache, fever, urticaria, bronchospasm, or hypotension and are managed by slowing or temporarily stopping the infusion, optimising premedication, and observing recovery before resuming. Severe reactions, including anaphylaxis, require permanent discontinuation. References: Ocrevus Prescribing Information, section 5.1 and section 2; Montalban X et al., Ocrelizumab versus placebo in primary progressive multiple sclerosis (ORATORIO), N Engl J Med 2017;376(3):209-220.
Frequently asked
Is this legal in Pakistan? Yes, when executed through the DRAP named-patient and personal-use framework with appropriate documentation, clinical rationale, and a licensed dispensing facility. The pathway is routinely used across oncology, rare disease, and immunology at Pakistani tertiary centers.
Will my private health insurance cover this? Cash-pay is the default posture. Cash-pay is the default posture in Pakistan; some employer plans cover specialty imports case-by-case. We supply documentation for your submission but do not process insurance claims.
How does cold-chain affect timing? Ocrevus ships refrigerated. We use validated packaging with continuous temperature monitoring, and arrival temperature data is logged on every shipment.
What if my physician has not filed a named-patient request before? Named-patient import is an institutional process most major Pakistani tertiary centers (Shaukat Khanum Memorial Cancer Hospital, Aga Khan University Hospital, and the Indus Hospital) have encountered. Our documentation kit is written for first-time applicants and tracks what DRAP reviewers commonly ask for.
Next step
For Ocrevus coordination in Pakistan, start your case at the portal or message us on WhatsApp. Our concierge case lead will respond within 24 hours.
Composite case examples. This content is for general information and does not constitute medical advice.